RxDoctor Payments Data

Laken Armstrong, NP

Family · Dothan, ALNPI 1982275491

Payments from drug & device makers

$1,199in general payments, 2019–2025

Across 54 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$289
  • Medtronic$151
  • Irhythm Technologies, Inc.$99
  • AstraZeneca$93
  • Scpharmaceuticals Inc.$77
  • Merck$76
  • plus $414 from 11 others

What the payments were for

  • Food & beverage$1,199100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,199 in reported general payments places this provider in the 65th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$40,625
Medicare patients
400
Services billed
698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban162$184,148
EntrestoSacubitril/Valsartan101$130,091
FarxigaDapagliflozin Propanediol83$84,116
XareltoRivaroxaban47$42,527
MultaqDronedarone Hcl22$30,871
Flecainide Acetate70$5,755
Ranolazine ErRanolazine52$5,361
Metoprolol Succinate263$4,999
Carvedilol282$3,360
Atorvastatin Calcium141$2,153
Ezetimibe33$2,123
Losartan Potassium137$2,115
Isosorbide Mononitrate ErIsosorbide Mononitrate124$1,575
SotalolSotalol Hcl54$1,436
Hydralazine Hcl72$1,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$184,148162 claims
NovartisEntresto$289$130,091101 claims
AstraZenecaFarxiga$93$84,11683 claims
Johnson & JohnsonXarelto$19$42,52747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,415 family providers in Alabama.

Other family in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →